Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have given written informed consent and be able to comply with all study requirements.~* Males or females aged 18-75, inclusive, at the time of Informed Consent.~* Females must be non-pregnant and non-lactating, and either surgically sterile or post- menopausal.~* Males must be surgically sterile, abstinent or using an acceptable contraceptive method.~* Body mass index (BMI) ≥ 27.0 - ≤ 39.0 kilograms per square meter (kg/m\^2).~* Diagnosis of Type 2 Diabetes Mellitus with an Hemoglobin A1C (HbA1c) ≥7.3% and ≤9.5% at screening.~* Must have been on a stable dose of Oral Antidiabetic Therapy for a minimum of 3 months prior to Screening.~* ≥ 10% liver fat prior to randomization assessed by MRI-PDFF.~* Stable body weight for at least 3 months before screening.~Exclusion Criteria:~* Clinically-significant abnormalities in medical history or physical examination.~* Clinically-significant abnormalities in screening laboratory values that would render a participant unsuitable for inclusion, per Sponsor.~* Evidence of uncorrected hypothyroidism or hyperthyroidism results at Screening.~* History of solid organ transplantation or renal dialysis.~* Clinically-significant complications of diabetes.~* Treatment with another Study Drug, biological agent, or device within one-month of screening.~* Known history or evidence of liver disease with a positive test for human immunodeficiency virus (HIV), Hepatitis C virus (HCV), or chronic Hepatitis B virus (HBV), or chronic liver disease other than NASH.~* Recent history of, or current drug or alcohol abuse.~* Current use of concomitant medications known to significantly impact body weight or that may cause liver toxicity, per Investigator~* Use of anticoagulant/Antiplatelet agents unless the dose has been stable for 4 weeks prior to the first dose of study drug\]~* Use of non-steroidal anti-inflammatory drug nimesulide or any other drug influencing coagulation (except lose-dose aspirin).~* Use of obeticholic acid or ursodeoxycholic acid~* Considered unsuitable for inclusion by the Principal Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IONIS DGAT2Rx (Type: EXPERIMENTAL): Single Dose of DGAT2Rx administered subcutaneously once weekly for 13 weeks
- Placebo (sterile saline 0.9) (Type: PLACEBO_COMPARATOR): Calculated volume to match active comparator administered subcutaneously once weekly for 13 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).